5-Amino-1MQ
Small-molecule NNMT inhibitor for adipose and metabolic research
5 mg vial · 50 mg vialpeptide · also known as Proxofim
A D-retro-inverso peptide that targets the FOXO4 and p53 interaction in senescence research.
FOXO4-DRI · 10 mg · Lyophilised vial
peptide · also known as Proxofim
A D-retro-inverso peptide that targets the FOXO4 and p53 interaction in senescence research.
In stock
FOXO4-DRI (Proxofim) is a cell-permeable peptide built from D-amino acids in reverse sequence order, designed to disrupt the binding of the transcription factor FOXO4 to p53 in senescent cells.
PubMed records selected for relevance to the compound. They describe published research, not outcomes or uses.
| Compound | FOXO4-DRI (Proxofim) |
|---|---|
| Type | Peptide |
| Selected presentation | 10 mg · Lyophilised vial |
| Form | Lyophilised powder in a sealed glass vial |
| Fill volume and concentration | Not applicable (lyophilised) |
| Label | CELVIVE wordmark, compound name, amount, "Purity: >99%", "For research use only" |
| Storage | -20 °C for long-term storage; 2 to 8 °C for under three months; away from light |
| Certificate of analysis | Not yet published online. Request for a batch |
| Research areas | Longevity & mitochondrial |
| All presentations | 10 mg lyophilised vial · € 150.00 |